- Home
- KEY vs ROIV Comparison
KEY vs ROIV Comparison
Compare KEY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEY | ROIV |
|---|---|---|
| Founded | 1825 | 2014 |
| Country | United States | United Kingdom |
| Employees | 17883 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KEY | ROIV |
|---|---|---|
| Price | $19.88 | $28.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $22.68 | ★ $27.56 |
| AVG Volume (30 Days) | ★ 15.1M | 5.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $15.33 | N/A |
| Revenue Next Year | $6.04 | $385.85 |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.73 | $8.73 |
| 52 Week High | $23.35 | $30.03 |
Technical Indicators
Market Signals| Indicator | KEY | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 63.29 |
| Support Level | $17.07 | $20.46 |
| Resistance Level | $21.69 | N/A |
| Average True Range (ATR) | 0.68 | 0.95 |
| MACD | -0.22 | -0.00 |
| Stochastic Oscillator | 16.00 | 66.80 |
Price Performance
Historical ComparisonAbout KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 15 states, but it is predominantly concentrated in its three largest markets: Ohio, New York, and Washington. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.